These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38458874)

  • 1. Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1.
    Lasrado N; Rössler A; Rowe M; Collier AY; Barouch DH
    Vaccine; 2024 Apr; 42(9):2117-2121. PubMed ID: 38458874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86.
    Lasrado N; Collier AY; Hachmann NP; Miller J; Rowe M; Schonberg ED; Rodrigues SL; LaPiana A; Patio RC; Anand T; Fisher J; Mazurek CR; Guan R; Wagh K; Theiler J; Korber BT; Barouch DH
    Vaccine; 2023 Nov; 41(47):6904-6909. PubMed ID: 37872011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
    Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
    mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.
    Favresse J; Gillot C; Cabo J; David C; Dogné JM; Douxfils J
    Int J Infect Dis; 2024 Jun; 143():107028. PubMed ID: 38583825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies.
    He Q; An Y; Zhou X; Xie H; Tao L; Li D; Zheng A; Li L; Xu Z; Yu S; Wang R; Hu H; Liu K; Wang Q; Dai L; Xu K; Gao GF
    Med; 2024 May; 5(5):401-413.e4. PubMed ID: 38574739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission.
    Benlarbi M; Ding S; Bélanger É; Tauzin A; Poujol R; Medjahed H; El Ferri O; Bo Y; Bourassa C; Hussin J; Fafard J; Pazgier M; Levade I; Abrams C; Côté M; Finzi A
    mBio; 2024 Aug; 15(8):e0090724. PubMed ID: 38953636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1.
    Wang Q; Guo Y; Schwanz LT; Mellis IA; Sun Y; Qu Y; Urtecho G; Valdez R; Stoneman E; Gordon A; Wang HH; Ho DD; Liu L
    Emerg Microbes Infect; 2024 Dec; 13(1):2359004. PubMed ID: 38779718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections.
    Medits I; Springer DN; Graninger M; Camp JV; Höltl E; Aberle SW; Traugott MT; Hoepler W; Deutsch J; Lammel O; Borsodi C; Puchhammer-Stöckl E; Zoufaly A; Weseslindtner L; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():946318. PubMed ID: 35928813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75.
    Wang Q; Iketani S; Li Z; Guo Y; Yeh AY; Liu M; Yu J; Sheng Z; Huang Y; Liu L; Ho DD
    Cell Host Microbe; 2022 Nov; 30(11):1512-1517.e4. PubMed ID: 36108630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.
    Moustsen-Helms IR; Bager P; Larsen TG; Møller FT; Vestergaard LS; Rasmussen M; Hansen CH;
    Lancet Infect Dis; 2024 Sep; 24(9):964-973. PubMed ID: 38761806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant.
    Khan K; Lustig G; Römer C; Reedoy K; Jule Z; Karim F; Ganga Y; Bernstein M; Baig Z; Jackson L; Mahlangu B; Mnguni A; Nzimande A; Stock N; Kekana D; Ntozini B; van Deventer C; Marshall T; Manickchund N; Gosnell BI; Lessells RJ; Karim QA; Abdool Karim SS; Moosa MS; de Oliveira T; von Gottberg A; Wolter N; Neher RA; Sigal A
    Nat Commun; 2023 Dec; 14(1):8078. PubMed ID: 38057313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
    da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycan masking of NTD loops with a chimeric RBD of the spike protein as a vaccine design strategy against emerging SARS-CoV-2 Omicron variants.
    Hung HC; Tan BF; Lin WS; Wu SC
    J Med Virol; 2024 Sep; 96(9):e29893. PubMed ID: 39192804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity.
    Muik A; Lui BG; Quandt J; Diao H; Fu Y; Bacher M; Gordon J; Toker A; Grosser J; Ozhelvaci O; Grikscheit K; Hoehl S; Kohmer N; Lustig Y; Regev-Yochay G; Ciesek S; Beguir K; Poran A; Vogler I; Türeci Ö; Sahin U
    Cell Rep; 2023 Aug; 42(8):112888. PubMed ID: 37527039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies to S2 domain of SARS-CoV-2 spike protein in Moderna mRNA vaccinated subjects sustain antibody-dependent NK cell-mediated cell cytotoxicity against Omicron BA.1.
    Balinsky CA; Jiang L; Jani V; Cheng Y; Zhang Z; Belinskaya T; Qiu Q; Long TK; Schilling MA; Jenkins SA; Corson KS; Martin NJ; Letizia AG; Hontz RD; Sun P
    Front Immunol; 2023; 14():1266829. PubMed ID: 38077368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75.
    Cao Y; Song W; Wang L; Liu P; Yue C; Jian F; Yu Y; Yisimayi A; Wang P; Wang Y; Zhu Q; Deng J; Fu W; Yu L; Zhang N; Wang J; Xiao T; An R; Wang J; Liu L; Yang S; Niu X; Gu Q; Shao F; Hao X; Meng B; Gupta RK; Jin R; Wang Y; Xie XS; Wang X
    Cell Host Microbe; 2022 Nov; 30(11):1527-1539.e5. PubMed ID: 36270286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron.
    Wang L; Møhlenberg M; Wang P; Zhou H
    Cytokine Growth Factor Rev; 2023 Apr; 70():13-25. PubMed ID: 36948931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis for the evolution and antibody evasion of SARS-CoV-2 BA.2.86 and JN.1 subvariants.
    Yang H; Guo H; Wang A; Cao L; Fan Q; Jiang J; Wang M; Lin L; Ge X; Wang H; Zhang R; Liao M; Yan R; Ju B; Zhang Z
    Nat Commun; 2024 Sep; 15(1):7715. PubMed ID: 39231977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
    Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
    J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1.
    Sohail MS; Ahmed SF; Quadeer AA; McKay MR
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.